索磷布韦维帕他韦治疗慢性丙型肝炎的效果  

Efficacy of Sofosbuvir and Velpatasvir in the treatment of chronic hepatitis C

作　　者：田杰 谢云云 TIAN Jie;XIE Yunyun(Department of Gastroenterology and Hepatology,Tianshui Hospital of Traditional Chinese Medicine,Gansu Province,Tianshui 741000,China)

机构地区：[1]甘肃省天水市中医医院脾胃肝病科,甘肃天水741000

出　　处：《中国当代医药》2025年第4期40-43,共4页China Modern Medicine

摘　　要：目的分析索磷布韦维帕他韦治疗慢性丙型肝炎患者的效果及影响。方法选取2020年1月至2021年12月天水市中医医院的50例慢性丙型肝炎患者作为研究对象,采用随机数字表法将其分成对照组和研究组,每组各25例。对照组给予聚乙二醇干扰素α-2a及利巴韦林,研究组给予索磷布韦维帕他韦。比较两组病毒应答率、肝功能、肝纤维化指标水平及不良反应。结果研究组的病毒应答率明显高于对照组,差异有统计学意义(P<0.05)。研究组治疗后凝血酶原(PTA)水平高、总胆红素(TBil)、丙氨酸转氨酶(ALT)、血清人层粘连蛋白(LN)、Ⅲ型前胶原氨基端原(PⅢNP)、透明质酸(HA)、天冬氨酸转氨酶(AST)水平低于对照组,差异有统计学意义(P<0.05)。研究组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论对于慢性丙型肝炎患者的治疗索磷布韦维帕他韦片的疗效优于聚乙二醇干扰素α-2a联合利巴韦林治疗效果明显,可以缓解患者临床症状,改善相关指标水平,进而提升其治疗效果和生活质量水平,值得在临床中广泛推广应用。Objective To analyze the efficacy and influence of Sofosbuvir and Velpatasvir in the treatment of chronic hepatitis C patients.Methods Fifty patients with chronic hepatitis C in Tianshui Hospital of Traditional Chinese Medicine from January 2020 to December 2021 were selected as the study objects,and were divided into control group and study group by random number table method,with 25 cases in each group.The control group was given Pegylated Interferon α-2a+Ribavirin,and the study group was given Sofosbuvir and Velpatasvir.The virus response rate,liver function,liver fibrosis index and adverse reactions were compared between the two groups.Results The virus response rate of study group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of prothrombin(PTA),total bilirubin(TBil),alanine transaminase(ALT),human laminin(LN),procollagen Ⅲ N-termi(PⅢNP),hyaluronic acid(HA)and aspartate transaminase(AST)in the study group were lower than those in the control group,with statistical significances(P<0.05).The total ncidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with chronic hepatitis C,the therapeutic effect of Sofobuvir and Vipatavir is better than that of Pegylated Interferon alpha-2a combined with Ribavirin,which can alleviate the clinical symptoms of patients,improve the level of related indicators,and further enhance the therapeutic effect and quality of life,which is worthy of widespread application in clinical practice.

关 键 词：索磷布韦 慢性丙型肝炎 临床指标 不良反应 

分 类 号：R512.63[医药卫生—内科学]